Celecoxib for familial adenomatous polyposis

Onsenal is a new preparation of the COX-2 inhibitor celecoxib, indicated for use in familial adenomatous polyposis (FAP). Patients with this condition develop large numbers of intestinal polyps that overexpress COX-2. Left untreated, these polyps eventually progress to colorectal cancer.

In a randomised, controlled trial in 83 patients with FAP, treatment with celecoxib for 6 months reduced the number of polyps by a mean of 28% (compared with a mean reduction of 5% for placebo). Celecoxib has been studied only for up to 6 months in FAP, and has not been shown to reduce the risk of cancer or the need for surgery.

View Onsenal drug record

Further information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more